Literature DB >> 26431145

Lumbar Sympathetic Block with Botulinum Toxin Type B for Complex Regional Pain Syndrome: A Case Study.

Eunjoo Choi, Chan Woo Cho1, Hye Young Kim, Pyung Bok Lee1, Francis Sahngun Nahm1.   

Abstract

Lumbar sympathetic block (LSB) is an effective method for relief of sympathetically mediated pain in the lower extremities. To prolong the sympathetic blockade, sympathetic destruction with alcohol or radiofrequency has been used. The pre-ganglionic sympathetic nerves are cholinergic, and botulinum toxin (BTX) has been found to inhibit the release of acetylcholine at the cholinergic nerve terminals. Moreover, BTX type B (BTX-B) is more convenient to use than BTX type A. Based on these findings, we performed LSB on the 2 patients with complex regional pain syndrome (CRPS) in the lower extremity. Levobupivacaine 0.25% 5 mL mixed with BTX-B 5,000 IU was given under fluoroscopic guidance. Two months after LSB with BTX-B, pain intensity and the Leeds assessment of neuropathic symptoms and signs (LANSS) score were significantly reduced. Allodynia and coldness disappeared and skin color came back to normal. In conclusion, BTX-B can produce an efficacious and durable sympathetic blocking effect on patients with CRPS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26431145

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  3 in total

1.  Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome.

Authors:  Yongki Lee; Chul Joong Lee; Eunjoo Choi; Pyung Bok Lee; Ho-Jin Lee; Francis Sahngun Nahm
Journal:  Toxins (Basel)       Date:  2018-04-19       Impact factor: 4.546

Review 2.  Botulinum Toxin for the Treatment of Neuropathic Pain.

Authors:  JungHyun Park; Hue Jung Park
Journal:  Toxins (Basel)       Date:  2017-08-24       Impact factor: 4.546

Review 3.  Botulinum Toxin for Central Neuropathic Pain.

Authors:  Jihye Park; Myung Eun Chung
Journal:  Toxins (Basel)       Date:  2018-06-01       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.